Greg Landes Email and Phone Number

•Evaluate client’s target discovery process, provides SWOT analysis on approach and considerations for enhancement. •Review all aspects of client’s target biology and suitability of target and disease indication for client biologics drug discovery platform.•Evaluate client’s biologics drug discovery platform including “naked” antibodies, enhanced antibodies, and ADCs while providing feedback for technology improvement.•Review individual drug discovery programs for clients identifying strengths/weaknesses and Go/No Go steps up to IND-enabling.•Assess client’s biologics drug discovery platform for automation amenability.•Provide relevant screening assays for “naked’ antibody and ADC drug discovery platform.•Identify critical preclinical in vitro assays and in vivo studies needed to support development activities for a biosimilar drug candidate. •Participate on client’s advisory board.•Lead national and international workshops on ADCs.

Accomplishments:•Manages Target Discovery, Antibody Research and Preclinical Development activities including oversight of the departments of Antibody Phage Display and Antibody Engineering, Biophysical Chemistry and Research Informatics, Preclinical Research and Project Management.•Reviews and guides early stage antibody drug discovery programs with an overarching principle of fewer programs of higher scientific quality. •Participates actively in scientific and strategic committees including those for collaboration programs, internal antibody drug program portfolio review, and the scientific advisory board portfolio review. Reviews progress and provides guidance for existing collaborations with external partners. •Fosters synergistic interactions with other organizations within Takeda Pharmaceutical Company on programs and technologies of common interest. Institutional interactions within TPC include those with Millennium, Takeda Cambridge, Takeda Research Investments, Pharmaceutical Research Laboratories I and II, etc. •Chairs the Safety Committee to establish practical and effective policies that are consistent with state and national guidelines while providing a safe place to work for TSF employees.•Advanced four programs to IND-enabling decision points in 3 years•Reports to the President and Chief Scientific Officer.

Accomplishments: •Created and managed the efforts of 6 groups: Adenovirus Target Validation, Biologics Discovery, Hybridoma, Protein Biochemistry, Process Science and Antibody Engineering in the identification of mouse antibodies to achieve proof-of-principle design goals in animal models and subsequently, antibody humanization and affinity maturation of the most potent lead molecules.•Grew direct and indirect reports from ~12 in 6/2004 to 34 in 2008 with an annual budget of ~$10MM. •Re-organized the department to increase the efficiency of pharmacological validation of drug targets resulting in a capacity to prosecute 12-16 early and mid-stage genetically validated programs at steady state. Identified weaknesses in pre-existing hybridoma technology and implemented several key steps to enable marked improvements in the quality and quantity of mouse antibody drug candidates identified per target. Expanded the utilization of recombinant adenovirus activities to include target validation of putatively secreted proteins as well as ecto domains of Type 1 and 2 membrane proteins. •Worked closely with pharmaceutical biology department heads (Immunology, Oncology, Endocrinology, Cardiology and Ophthalmology) and DM/PK to plan, design and interpret relevant animal pharmacology models. •Participated actively at multiple levels in scientific and strategic committees including project working groups for individual drug discovery programs, portfolio drug discovery committee, and the scientific executive committee. A key member of joint steering committees for alliances with corporate partners including Genentech, Organon and XOMA.•Advanced two programs to IND-enabling decision points.•Reported to the Chief Science Officer.

Accomplishments: •Managed the efforts of 5 groups: Molecular Biology, Antibody Technologies, Phage Display, Assay Development and Preclinical Biology in the identification and characterization of fully human antibody product candidates to treat human diseases. Direct and indirect reports grew from 20 in 5/2000 to greater than 40 by 7/2001 with an annual budget of $12MM. •Restructured the Antibody Technologies Group resulting in increased efficiency of prosecuting drug targets as well as marked improvements in the quality and quantity of antibody drug candidates identified per target. •Upon reorganization in 8/2001, led the efforts of Assay Development and Phage Display in the validation of putative targets, development of cell-based binding assays and functional screening assays, and identification of product candidates for targeted therapy. Managed 25 direct and indirect reports with an annual budget of $8MM. •Evaluated novel discovery platforms and technologies to enhance the quality of target and product candidates in the product discovery pipeline. •Identified multiple antibody drug candidates for Abgenix, Curagen, Amgen, Pfizer and Biogen that advanced to clinical development. •Participated at the senior management level in cross-functional committees to develop, manage and resource Abgenix’s drug development portfolio. Managed and participated in multiple joint steering committees with corporate partners to guide collaborative product candidate programs. Chaired the Scientific Advisory Board and engaged their active involvement in quarterly meetings. Led the Institutional Biosafety Committee and increased the annual project registrations almost four fold while diversifying the registrations to include new research areas such as immunoconjugates (in vitro and in vivo), medium scale recombinant protein expression (>10L) and large scale recombinant protein expression (2000L).•Reported to the Chief Science Officer.

Accomplishments:•Staffed, equipped, and integrated a sequence-based (SAGE) gene expression analysis team into the corporate genomics program for the discovery of targets for therapeutic development, particularly tumor antigen discovery. •Managed 8 direct reports and 27 indirect reports including working with project heads responsible for the activities of Gene Expression and Analysis, Functional Genomics, Molecular Profiling, Mutation Scanning, Bioinformatics and Positional Cloning. Managed an annual budget of $8MM. •Reviewed all corporate science projects as part of the senior scientific management team. •Represented the corporate genomic interests at national and international scientific and business meetings. •Overcame limitations of transcriptional mapping via exon trapping by modifying pSPL3 to eliminate its major cryptic spliced product and then enabled shotgun subcloning of fragments from beta-lactamase expressing cosmids.•Directed an effort that cloned the Autosomal Dominant Polycystic Kidney Disease Type 1 (PKD1) interval in P1 phage, transcriptionally mapped the resulting 700-kb segment by both cDNA selection and exon trapping, identified multiple transcriptional units including PKD1, TSC2, a novel human netrin gene, a new member of the ABC gene family, and several novel genes of unknown function. •Led a multi-institutional team that was the first to sequence, computationally analyze, and report the complete PKD1 gene, including the identification of the largest polypyrimidine tract present in germline human DNA.•Managed a team that was the first to assemble, express, characterize and report the 14.3 kb full-length cDNA for the PKD1 gene; 8 direct and indirect reports with an annual budget of $2MM. •Directed a transcriptional mapping effort that resulted in the identification of the gene responsible for a major cardiac arrhythmia, LQT1 (KVLQT1).•Reported to the Senior VP of Genetics and Genomics.

Acquired by Genzyme Corp. in 1989.Accomplishments: -Lead a group of 8 scientists in the development and optimization of non-isotopic labeling and detection of DNA probes; managed an annual budget of $1MM.-Proposed, designed, optimized and produced the first commercial DNA hybridization probe set for the detection of Salmonella in food.-Designed and generated vector constructs for the expression of Protein C in C127 cells using Bovine Papilloma Virus-based vectors.-Constructed a novel site-directed mutant of Protein C, Asp71Glu, which demonstrated that post-transitional -hydroxylation of Asp71 in Protein C was crucial for biological activity.-Optimized and applied a filter lift technique to reveal primary mammalian cell transfectants expressing high levels of secreted recombinant proteins (erythropoietin and Protein C). -Proposed, optimized and demonstrated a chemical conjugation methodology for coupling DNA to enzymes, fluorochromes, and haptens that enabled their use as non-isotopic hybridization probes.